HomeTagsLeukemia

Tag: Leukemia

Galinpepimut-S shows a 41% reduction...

SELLAS Life Sciences Group has reported positive...

Galinpepimut-S shows a 41% reduction in risk of death in Phase 3 AML trial

SELLAS Life Sciences Group has reported positive topline results from its pivotal Phase 3 REGAL trial, in which its investigational WT1-targeted immunotherapeutic vaccine galinpepimut-S (GPS) met the primary endpoint of overall survival in patients with acute myeloid leukaemia (AML). The treatment was associated with a 41% reduction in the risk of death compared with best available treatment, with median overall survival of 24.0 months versus 14.7 months. Phase 3 REGAL trial demonstrates an overall survival benefit The global, randomised, open-label REGAL trial evaluated galinpepimut-S as maintenance monotherapy in patients with AML...

Galinpepimut-S shows a...

SELLAS Life Sciences Group has reported positive topline results from its pivotal Phase 3 REGAL trial, in which its investigational WT1-targeted immunotherapeutic vaccine galinpepimut-S...
spot_img

Create a website from scratch

With Newspaper Theme you can drag and drop elements onto a page and customize them to perfection. Try it out today and create the perfect site to express yourself!